Table 3.

In vitro anticancer activity of selected oximes.

Compound	Cells	Concentration range (µM)	Effect/Mechanism a	Ref.
1	Pancreatic ductal adenocarcinoma cells	1–10	↓ p-CDK1/cyclinB1	[80]
	MG63 and U2-OS osteosarcoma	1–10	↓ CDK2/4, FAK	[81]
	Cholangiocarcinoma linesNOZ, HuCCT1, OCUG-1, and OZ	1–60		[82]
11, 14	MDA-MB-231-TXSA breast cancer	10–50	↑ Caspase-3	[83]
14	Thyroid carcinoma	1–10	↑ Caspase-3	[84]
	Neuroblastoma SH-SY5Y	10–100		[85]
16	MG63 and Saos-2 osteosarcoma	1–30	↑ AMPK	[86]
	MV4-11 and FLT3/D835Y expressed MOLM14	IC50 = 0.001 (toward FLT3)	↓ FLT3	[61]
17	3Y1-B, SR-3Y1, NRK,KNRK5.2 cells	IC50 = 0.025 (toward v-Src)	↓ v-Src activity; ↓ Raf-1 expression	[34]
26	Human colorectal carcinoma HCT-116, human lung cancer A549, human liver carcinoma Huh7, human leukemia HL60	0.1–1	Inhibitor of PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ	[39]

^a ↓ and ↑ indicate decreasing or increasing enzyme activity or protein expression after treatment with compound, respectively.